Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Effect of topical diclofenac on blood-aqueous barrier breakdown following microcoaxial phacoemulsification

Poster Details

First Author: S.Ben Yahia TUNISIA

Co Author(s):    R. Kahloun   S. Ben Amor   B. Jelliti   S. Zaouali   M. Khairallah        

Abstract Details

Purpose:

To study the effect of topical diclofenac 0.1% on postoperative blood-aqueous barrier breakdown following microcoaxial phacoemulsification.

Setting:

Department of Ophthalmology, Fattouma Bourguiba University Hospital, Monastir, Tunisia.

Methods:

One-hundred-fifty patients with no eye disease other than cataract who underwent microcoaxial (2.2 mm) phacoemulsification and foldable intraocular lens implantation were included in this study. After cataract surgery, all patients were treated only with topical diclofenac 0.1% four times daily for 4 weeks. No concomitant corticosteroid use was allowed. The inflammatory reaction in the anterior chamber was measured with laser flare photometry preoperatively and 1, 7, 14, and 28 days postoperatively.

Results:

Mean preoperative aqueous flare (in photon counts per millisecond) was 8,3 ± 2,66 ph/ms. Following cataract surgery, mean aqueous flare increased to 39± 2,7 on day 1, and decreased to 16.8 +/- 2.03 on day 7, to 12.7 +/- 1.6 on day 14, and to 10.4 +/- 1.3 on day 28. No postoperative complications such as fibrin formation, synechiae, or endophthalmitis were observed in any of the patients. No significant side effects related to the study treatment were recorded.

Conclusions:

Topical diclofenac can effectively be used without concurrent administration of corticosteroids to control postoperative inflammation after microcoaxial phacoemulsification.

Financial Disclosure:

NONE

Back to Poster listing